1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP)- formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis

Molecular Medicine

Volumn 14, Issue 7-8, 2008, Pages 365-373

  Kornek, Miroslaw ^a,c   Lukacs Kornek, Veronika ^b   Limmer, Andreas ^b   Raskopf, Esther ^a   Becker, Ursula ^a   Klöckner, Maren ^a   Sauerbruch, Tilman ^a   Schmitz, Volker ^a,c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Institute of Molecular Medicine and Experimental Immunology   (Germany)

^c Medizinische Klinik und Poliklinik I   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; BETA INTERFERON; SMALL INTERFERING RNA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE SILENCING; IMMUNE SYSTEM; IMMUNOSTIMULATION; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE THERAPY; IMMUNOCONJUGATES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MICE, INBRED C3H; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; QUATERNARY AMMONIUM COMPOUNDS; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROTOPIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48149090024     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2008-00003.Kornek     Document Type: Article

References (48)

1. Anthony PP et al. (1978) The morphology of cirrhosis: recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J. Clin. Pathol. 31:395-414.
2. Guo JT et al. (2000) Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J. Virol. 74:1495-505.
3. Liang TJ, Heller T. (2004) Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127: S62-71.
4. Johnson RC. (1997) Hepatocellular carcinoma. Hepatogastroenterology 44:307-12.
5. Llovet JM, Burroughs A, Bruix J. (2003) Hepatocellular carcinoma. Lancet 362:1907-17.
6. Bluteau O et al. (2002) Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 32:312-5.
7. Camma C, Giunta M, Andreone P, Craxi A. (2001) Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol. 34:593-602.
8. Kornek M et al. (2008) Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis. Liver Int. 28:509-18.
9. Kuriyama S et al. (1999) Hepatocellular carcinoma in an orthotopic mouse model metastasizes intrahepatically in cirrhotic but not in normal liver. Int. J. Cancer 80:471-6.
10. Ferrara N, Kerbel RS. (2005) Angiogenesis as a therapeutic target. Nature 438:967-74.
11. Kim SH et al. (2006) PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116:123-9.
12. Mulkeen AL et al. (2006) Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. Arch. Surg. 141:367-74.
13. Jia RB et al. (2007) VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 39:108-15.
14. Shen HL et al. (2007) Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk. Res. 31:515-21.
15. Kornek M et al. (2006) Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J. Hepatol. 45: 370-6.
16. Kornek M et al. (2007) Experimental orthotopic HCC growth is accelerated in hepatic fibrosis. J. Hepatol. 46:S82-3.
17. Kornek M, Raskopf E, Tolba R, Becker U, Klöckner M, Sauerbruch T, Schmitz V. (2008) Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of proangiogenic and prometastatic factors in murine liver fibrosis. Liver Int. 28(4):509-18.
18. Filleur S et al. (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63:3919-22.
19. Takei Y et al. (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64:3365-70.
20. Verma UN et al. (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9:1291-300.
21. Aigner A. (2006) Delivery systems for the direct application of siRNAs to Induce RNA interference (RNAi) in vivo. J. Biomed. Biotechnol. 2006:71659.
22. Ishak K et al. (1995) Histological grading and staging of chronic hepatitis. J. Hepatol. 22:696-9.
23. Judge AD et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23:457-62.
24. Hornung V et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11:263-70.
25. Schlee M, Hornung V, Hartmann G. (2006) siRNA and isRNA: two edges of one sword. Mol. Ther. 14:463-70.
26. Khazanov E, Simberg D, Barenholz Y. (2006) Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med. 8:998-1007.
27. Kim WJ et al. (2006) Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adeno't takcarcinoma. Mol. Ther. 14:343-50.
28. Niola F et al. (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol. Ther. 5:174-9.
29. Raskopf E et al. (2005) Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model. Hepatology 41:1233-40.
30. Schmitz V et al. (2006) Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice. Gene Ther. 13:1198-205.
31. Schmitz V et al. (2004) Establishment of an orthotopic tumour model for hepatocellular carcinoma and non-invasive in vivo tumour imaging by high resolution ultrasound in mice. J. Hepatol. 40:787-91.
32. Raskopf E et al. (2007) Posttranscriptional VEGF inhibition reduces tumor growth in an experimental murine HCC model. J. Hepatol. 46:S151.
33. Roberts N et al. (2006) Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 66:2650-7.
34. Liu L et al. (2003) Poly(cationic lipid)-mediated in vivo gene delivery to mouse liver. Gene Ther. 10:180-7.
35. Hamm S et al. (2007) Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int. Immunol. 19:297-304.
36. Meier A et al. (2007) MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 81:8180-91.
37. Hertzog PJ, Hwang SY, Kola I. (1994) Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev. 39:226-32.
38. Hong YK et al. (2000) Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin. Cancer Res. 6:3354-60.
39. Izawa JI et al. (2002) Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res. 8:1258-70.
40. Cao G et al. (2001) Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther. 8:497-505.
41. Wang L et al. (2000) High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32:43-8.
42. Ikeda K et al. (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-32.
43. Ogasawara S et al. (2007) Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J. Interferon Cytokine Res. 27:507-16.
44. Shweiki D, Itin A, Soffer D, Keshet E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-5.
45. Forsythe JA et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-13.
46. Jones DT, Harris AL. (2006) Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol. Cancer Ther. 5:2193-202.
47. Gillespie DL et al. (2007) Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo. Clin. Cancer Res. 13:2441-8.
48. Bocci G et al. (2004) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64:6616-25.